Inhibition of Alpha-synuclein Aggregation by Multifunctional Dopamine Agonists Assessed by a Novel in Vitro Assay and an in Vivo Drosophila Synucleinopathy Model

Overview

Journal Sci Rep

Specialty Science

Date 2016 Dec 6

PMID 27917933

Citations 19

Authors

Deepthi Yedlapudi

Gnanada S Joshi

Dan Luo

Sokol V Todi

Aloke K Dutta

Affiliations

Soon will be listed here.

Abstract

Aggregation of alpha synuclein (α-syn) leading to dopaminergic neuronal death has been recognized as one of the main pathogenic factors in the initiation and progression of Parkinson's disease (PD). Consequently, α-syn has been targeted for the development of therapeutics for PD. We have developed a novel assay to screen compounds with α-syn modulating properties by mimicking recent findings from in vivo animal studies involving intrastriatal administration of pre-formed fibrils in mice, resulting in increased α-syn pathology accompanying the formation of Lewy-body (LB) type inclusions. We found that in vitro generated α-syn pre-formed fibrils induce seeding of α-syn monomers to produce aggregates in a dose-and time-dependent manner under static conditions in vitro. These aggregates were toxic towards rat pheochromocytoma cells (PC12). Our novel multifunctional dopamine agonists D-519 and D-520 exhibited significant neuroprotection in this assay, while their parent molecules did not. The neuroprotective properties of our compounds were further evaluated in a Drosophila model of synucleinopathy. Both of our compounds showed protective properties in fly eyes against the toxicity caused by α-syn. Thus, our in vitro results on modulation of aggregation and toxicity of α-syn by our novel assay were further validated with the in vivo experiments.

Citing Articles

The role of the endolysosomal pathway in α-synuclein pathogenesis in Parkinson's disease.

Smith J, Mellick G, Sykes A Front Cell Neurosci. 2023; 16:1081426.

PMID: 36704248 PMC: 9871505. DOI: 10.3389/fncel.2022.1081426.

Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein.

Dinda B, Das B, Biswas S, Sharma H, Armstrong C, Yedlapudi D Bioorg Med Chem. 2022; 78:117131.

PMID: 36571976 PMC: 9898996. DOI: 10.1016/j.bmc.2022.117131.

Pyrogallol, Corilagin and Chebulagic acid target the "fuzzy coat" of alpha-synuclein to inhibit the fibrillization of the protein.

Bopardikar M, Ainavarapu S, Hosur R RSC Adv. 2022; 12(55):35770-35777.

PMID: 36545068 PMC: 9749937. DOI: 10.1039/d2ra04358k.

Triphala inhibits alpha-synuclein fibrillization and their interaction study by NMR provides insights into the self-association of the protein.

Bopardikar M, Bhattacharya A, Rao Kakita V, Rachineni K, Borde L, Choudhary S RSC Adv. 2022; 9(49):28470-28477.

PMID: 35529629 PMC: 9071048. DOI: 10.1039/c9ra05551g.

Co-Aggregation of S100A9 with DOPA and Cyclen-Based Compounds Manifested in Amyloid Fibril Thickening without Altering Rates of Self-Assembly.

Arabuli L, Iashchishyn I, Romanova N, Musteikyte G, Smirnovas V, Chaudhary H Int J Mol Sci. 2021; 22(16).

PMID: 34445262 PMC: 8395260. DOI: 10.3390/ijms22168556.

References

Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M . Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 1994; 657(1-2):207-13. DOI: 10.1016/0006-8993(94)90969-5. View

Liu I, Uversky V, Munishkina L, Fink A, Halfter W, Cole G . Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology. 2005; 15(12):1320-31. DOI: 10.1093/glycob/cwj014. View

Luk K, Song C, OBrien P, Stieber A, Branch J, Brunden K . Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009; 106(47):20051-6. PMC: 2785290. DOI: 10.1073/pnas.0908005106. View

Asanuma M, Kondo Y, Iwata E, Ogawa N . Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 1998; 790(1-2):202-8. DOI: 10.1016/s0006-8993(97)01521-7. View

Uversky V, Cooper E, Bower K, Li J, Fink A . Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 2002; 515(1-3):99-103. DOI: 10.1016/s0014-5793(02)02446-8. View

Cookson M . alpha-Synuclein and neuronal cell death. Mol Neurodegener. 2009; 4:9. PMC: 2646729. DOI: 10.1186/1750-1326-4-9. View

Manning-Bog A, McCormack A, Li J, Uversky V, Fink A, Di Monte D . The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem. 2001; 277(3):1641-4. DOI: 10.1074/jbc.C100560200. View

Narhi L, Wood S, Steavenson S, Jiang Y, Wu G, Anafi D . Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem. 1999; 274(14):9843-6. DOI: 10.1074/jbc.274.14.9843. View

Dutta A, Venkataraman S, Fei X, Kolhatkar R, Zhang S, Reith M . Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. Bioorg Med Chem. 2004; 12(16):4361-73. DOI: 10.1016/j.bmc.2004.06.019. View

10.

Wu M, Brudzynski S, MOGENSON G . Differential effects of quinpirole in the nucleus accumbens depending on the initial level of locomotor activity. Brain Res Bull. 1993; 32(4):395-8. DOI: 10.1016/0361-9230(93)90206-q. View

11.

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S . Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015; 14(8):855-866. PMC: 5217462. DOI: 10.1016/S1474-4422(15)00006-X. View

12.

Uversky V, Li J, Fink A . Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001; 276(47):44284-96. DOI: 10.1074/jbc.M105343200. View

13.

Tsou W, Hosking R, Burr A, Sutton J, Ouyang M, Du X . DnaJ-1 and karyopherin α3 suppress degeneration in a new Drosophila model of Spinocerebellar Ataxia Type 6. Hum Mol Genet. 2015; 24(15):4385-96. PMC: 4492400. DOI: 10.1093/hmg/ddv174. View

14.

Shtilerman M, Ding T, Lansbury Jr P . Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?. Biochemistry. 2002; 41(12):3855-60. DOI: 10.1021/bi0120906. View

15.

Recchia A, Debetto P, Negro A, Guidolin D, Skaper S, Giusti P . Alpha-synuclein and Parkinson's disease. FASEB J. 2004; 18(6):617-26. DOI: 10.1096/fj.03-0338rev. View

16.

Shevchik V, Condemine G . Characterization of DsbC, a periplasmic protein of Erwinia chrysanthemi and Escherichia coli with disulfide isomerase activity. EMBO J. 1994; 13(8):2007-12. PMC: 395043. DOI: 10.1002/j.1460-2075.1994.tb06470.x. View

17.

Serpell L, Berriman J, Jakes R, Goedert M, Crowther R . Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A. 2000; 97(9):4897-902. PMC: 18329. DOI: 10.1073/pnas.97.9.4897. View

18.

Huang C, Ren G, Zhou H, Wang C . A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr Purif. 2005; 42(1):173-7. DOI: 10.1016/j.pep.2005.02.014. View

19.

Zhu M, Fink A . Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem. 2003; 278(19):16873-7. DOI: 10.1074/jbc.M210136200. View

20.

Burr A, Tsou W, Ristic G, Todi S . Using membrane-targeted green fluorescent protein to monitor neurotoxic protein-dependent degeneration of Drosophila eyes. J Neurosci Res. 2014; 92(9):1100-9. PMC: 4144675. DOI: 10.1002/jnr.23395. View